Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289


Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma.

Oliveira-Ferrer L, Milde-Langosch K, Eylmann K, Rossberg M, Müller V, Schmalfeldt B, Witzel I, Wellbrock J, Fiedler W.

Int J Mol Sci. 2020 Jan 17;21(2). pii: E602. doi: 10.3390/ijms21020602.


Daily energy expenditure in white storks is lower after fledging than in the nest.

Flack A, Schaeffer PJ, Taylor JRE, Müller I, Wikelski M, Fiedler W.

J Exp Biol. 2020 Jan 28;223(Pt 2). pii: jeb219337. doi: 10.1242/jeb.219337.


Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H.

J Clin Oncol. 2020 Feb 20;38(6):623-632. doi: 10.1200/JCO.19.01406. Epub 2019 Dec 18.


Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.

Stamm H, Oliveira-Ferrer L, Grossjohann EM, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W, Wellbrock J.

Oncoimmunology. 2019 Oct 12;8(12):e1674605. doi: 10.1080/2162402X.2019.1674605. eCollection 2019.


The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia.

Velthaus A, Cornils K, Hennigs JK, Grüb S, Stamm H, Wicklein D, Bokemeyer C, Heuser M, Windhorst S, Fiedler W, Wellbrock J.

Cancers (Basel). 2019 Oct 26;11(11). pii: E1663. doi: 10.3390/cancers11111663.


Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0589-3. [Epub ahead of print] No abstract available.


Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.


"Closer-to-home" strategy benefits juvenile survival in a long-distance migratory bird.

Cheng Y, Fiedler W, Wikelski M, Flack A.

Ecol Evol. 2019 Jul 23;9(16):8945-8952. doi: 10.1002/ece3.5395. eCollection 2019 Aug.


Fly with the flock: immersive solutions for animal movement visualization and analytics.

Klein K, Sommer B, Nim HT, Flack A, Safi K, Nagy M, Feyer SP, Zhang Y, Rehberg K, Gluschkow A, Quetting M, Fiedler W, Wikelski M, Schreiber F.

J R Soc Interface. 2019 Apr 26;16(153):20180794. doi: 10.1098/rsif.2018.0794.


Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ.

J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.


Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.

Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.


Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M.

Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.


A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.

Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J, Bug G, Schlenk RF, Krug U, Goeldner RG, Hilbert J, Taube T, Ottmann OG.

Br J Haematol. 2019 May;185(3):583-587. doi: 10.1111/bjh.15563. Epub 2018 Nov 19. No abstract available.


Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).

Krauter J, Fiedler W, Schlenk RF, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik VI, Becker H, Greil C, Reimer P, Götze KS, Döhner H, Ganser A, Heuser M.

Br J Haematol. 2018 Oct;183(2):235-241. doi: 10.1111/bjh.15546.


Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look.

Behrmann L, Wellbrock J, Fiedler W.

Front Oncol. 2018 Oct 12;8:444. doi: 10.3389/fonc.2018.00444. eCollection 2018. Review.


A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.

Kebenko M, Goebeler ME, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W.

Oncoimmunology. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710. eCollection 2018.


Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.

Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, Medeiros BC, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons BP, Riehl T, Colburn D.

Br J Haematol. 2019 May;185(3):595-598. doi: 10.1111/bjh.15571. Epub 2018 Sep 11. No abstract available.


Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M.

Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.


Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.

Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk RF.

Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31. No abstract available.


Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Stamm H, Wellbrock J, Fiedler W.

Mamm Genome. 2018 Dec;29(11-12):694-702. doi: 10.1007/s00335-018-9770-7. Epub 2018 Aug 21. Review.


Early arrival at breeding grounds: Causes, costs and a trade-off with overwintering latitude.

Rotics S, Kaatz M, Turjeman S, Zurell D, Wikelski M, Sapir N, Eggers U, Fiedler W, Jeltsch F, Nathan R.

J Anim Ecol. 2018 Nov;87(6):1627-1638. doi: 10.1111/1365-2656.12898. Epub 2018 Oct 3.


Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S.

ESMO Open. 2018 Jun 23;3(4):e000381. doi: 10.1136/esmoopen-2018-000381. eCollection 2018.


Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression.

Sakhnevych SS, Yasinska IM, Bratt AM, Benlaouer O, Gonçalves Silva I, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Gibbs BF, Ushkaryov YA, Sumbayev VV.

Cell Mol Immunol. 2018 Nov;15(11):994-997. doi: 10.1038/s41423-018-0053-8. Epub 2018 Jun 15. No abstract available.


High mobility group box 1 (HMGB1) acts as an "alarmin" to promote acute myeloid leukaemia progression.

Yasinska IM, Gonçalves Silva I, Sakhnevych SS, Ruegg L, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Bardelli M, Varani L, Raap U, Berger S, Gibbs BF, Fasler-Kan E, Sumbayev VV.

Oncoimmunology. 2018 Feb 27;7(6):e1438109. doi: 10.1080/2162402X.2018.1438109. eCollection 2018.


Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.

Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W.

Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31.


From local collective behavior to global migratory patterns in white storks.

Flack A, Nagy M, Fiedler W, Couzin ID, Wikelski M.

Science. 2018 May 25;360(6391):911-914. doi: 10.1126/science.aap7781.


Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Jul;32(7):1621-1630. doi: 10.1038/s41375-018-0129-6. Epub 2018 Apr 17.


Synchronization, coordination and collective sensing during thermalling flight of freely migrating white storks.

Nagy M, Couzin ID, Fiedler W, Wikelski M, Flack A.

Philos Trans R Soc Lond B Biol Sci. 2018 May 19;373(1746). pii: 20170011. doi: 10.1098/rstb.2017.0011.


Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates.

Yasinska IM, Ceccone G, Ojea-Jimenez I, Ponti J, Hussain R, Siligardi G, Berger SM, Fasler-Kan E, Bardelli M, Varani L, Fiedler W, Wellbrock J, Raap U, Gibbs BF, Calzolai L, Sumbayev VV.

Nanoscale. 2018 Mar 29;10(13):5827-5833. doi: 10.1039/c7nr09436a.


Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.

Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L.

ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018.


Moving in the Anthropocene: Global reductions in terrestrial mammalian movements.

Tucker MA, Böhning-Gaese K, Fagan WF, Fryxell JM, Van Moorter B, Alberts SC, Ali AH, Allen AM, Attias N, Avgar T, Bartlam-Brooks H, Bayarbaatar B, Belant JL, Bertassoni A, Beyer D, Bidner L, van Beest FM, Blake S, Blaum N, Bracis C, Brown D, de Bruyn PJN, Cagnacci F, Calabrese JM, Camilo-Alves C, Chamaillé-Jammes S, Chiaradia A, Davidson SC, Dennis T, DeStefano S, Diefenbach D, Douglas-Hamilton I, Fennessy J, Fichtel C, Fiedler W, Fischer C, Fischhoff I, Fleming CH, Ford AT, Fritz SA, Gehr B, Goheen JR, Gurarie E, Hebblewhite M, Heurich M, Hewison AJM, Hof C, Hurme E, Isbell LA, Janssen R, Jeltsch F, Kaczensky P, Kane A, Kappeler PM, Kauffman M, Kays R, Kimuyu D, Koch F, Kranstauber B, LaPoint S, Leimgruber P, Linnell JDC, López-López P, Markham AC, Mattisson J, Medici EP, Mellone U, Merrill E, de Miranda Mourão G, Morato RG, Morellet N, Morrison TA, Díaz-Muñoz SL, Mysterud A, Nandintsetseg D, Nathan R, Niamir A, Odden J, O'Hara RB, Oliveira-Santos LGR, Olson KA, Patterson BD, Cunha de Paula R, Pedrotti L, Reineking B, Rimmler M, Rogers TL, Rolandsen CM, Rosenberry CS, Rubenstein DI, Safi K, Saïd S, Sapir N, Sawyer H, Schmidt NM, Selva N, Sergiel A, Shiilegdamba E, Silva JP, Singh N, Solberg EJ, Spiegel O, Strand O, Sundaresan S, Ullmann W, Voigt U, Wall J, Wattles D, Wikelski M, Wilmers CC, Wilson JW, Wittemyer G, Zięba F, Zwijacz-Kozica T, Mueller T.

Science. 2018 Jan 26;359(6374):466-469. doi: 10.1126/science.aam9712.


Acute hepatitis as a prequel to very severe aplastic anemia.

Weiler-Normann C, Hartl J, Weidemann S, von Pein UM, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M.

Z Gastroenterol. 2018 Jan;56(1):51-54. doi: 10.1055/s-0043-121737. Epub 2018 Jan 9.


SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model.

Täger M, Horn S, Latuske E, Ehm P, Schaks M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J, Jücker M.

Gene Ther. 2017 Nov;24(11):749-753. doi: 10.1038/gt.2017.88. Epub 2017 Nov 16.


Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.


Current and future suitability of wintering grounds for a long-distance migratory raptor.

Kassara C, Gangoso L, Mellone U, Piasevoli G, Hadjikyriakou TG, Tsiopelas N, Giokas S, López-López P, Urios V, Figuerola J, Silva R, Bouten W, Kirschel ANG, Virani MZ, Fiedler W, Berthold P, Gschweng M.

Sci Rep. 2017 Aug 18;7(1):8798. doi: 10.1038/s41598-017-08753-w.


The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells.

Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, Berger SM, Ushkaryov YA, Gibbs BF, Fasler-Kan E, Sumbayev VV.

EBioMedicine. 2017 Aug;22:44-57. doi: 10.1016/j.ebiom.2017.07.018. Epub 2017 Jul 19.


DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.


Bio-logging, new technologies to study conservation physiology on the move: a case study on annual survival of Himalayan vultures.

Sherub S, Fiedler W, Duriez O, Wikelski M.

J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2017 Jul;203(6-7):531-542. doi: 10.1007/s00359-017-1180-x. Epub 2017 Jun 13.


Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.


Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.

Latuske EM, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J.

Oncotarget. 2017 Apr 25;8(17):29187-29201. doi: 10.18632/oncotarget.16304.


The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.

Both A, Krauter J, Damm F, Thol F, Göhring G, Heuser M, Ottmann O, Lübbert M, Wattad M, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Schlegelberger B, Heil G, Ganser A, Wagner K.

Ann Hematol. 2017 Jun;96(6):895-904. doi: 10.1007/s00277-017-2967-0. Epub 2017 Mar 22.


Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; the German-Austrian AMLSG.

Leukemia. 2017 May;31(5):1217-1220. doi: 10.1038/leu.2017.22. Epub 2017 Jan 18. No abstract available.


Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.

Leukemia. 2017 Apr;31(4):1012-1015. doi: 10.1038/leu.2017.18. Epub 2017 Jan 16. No abstract available.


Wind estimation based on thermal soaring of birds.

Weinzierl R, Bohrer G, Kranstauber B, Fiedler W, Wikelski M, Flack A.

Ecol Evol. 2016 Nov 15;6(24):8706-8718. doi: 10.1002/ece3.2585. eCollection 2016 Dec.


Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk RF, Döhner K, Döhner H, Ganser A, Heuser M.

Leukemia. 2017 Jun;31(6):1286-1295. doi: 10.1038/leu.2016.345. Epub 2016 Nov 24.


All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016 Oct 3.


Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.

Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.


Patterns and biases in climate change research on amphibians and reptiles: a systematic review.

Winter M, Fiedler W, Hochachka WM, Koehncke A, Meiri S, De la Riva I.

R Soc Open Sci. 2016 Sep 7;3(9):160158. eCollection 2016 Sep.


Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome.

Said SM, Fidler ME, Valeri AM, McCann B, Fiedler W, Cornell LD, Alexander MP, Alkhunaizi AM, Sullivan A, Cramer CH, Hogan MC, Nasr SH.

Kidney Int Rep. 2016 Sep 29;2(1):44-52. doi: 10.1016/j.ekir.2016.09.056. eCollection 2017 Jan.


Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.

Supplemental Content

Loading ...
Support Center